These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 28158170)

  • 1. Platelet-Rich Plasma Therapy and Antithrombotic Drugs.
    Anitua E; Prado R; Orive G
    Pain Physician; 2017 Feb; 20(2):E335-E336. PubMed ID: 28158170
    [No Abstract]   [Full Text] [Related]  

  • 2. In Response to: Platelet-Rich Plasma Therapy and Antithrombotic Drugs.
    Danesh H
    Pain Physician; 2017 Feb; 20(2):E337. PubMed ID: 28158171
    [No Abstract]   [Full Text] [Related]  

  • 3. Timing of Platelet Rich Plasma Injections During Antithrombotic Therapy.
    Ramsook RR; Danesh H
    Pain Physician; 2016; 19(7):E1055-61. PubMed ID: 27676677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production of platelet-rich plasma gel from elderly patients under antithrombotic drugs: Perspectives in chronic wounds care.
    Velier M; Magalon J; Daumas A; Cassar M; Francois P; Ghazouane A; Philandrianos C; Bertrand B; Frere C; Bernot D; Villani P; George FD; Sabatier F
    Platelets; 2018 Jul; 29(5):496-503. PubMed ID: 28805478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antithrombotic effect of aurin tricarboxylic acid in the guinea pig is not solely due to its interaction with the von Willebrand factor-GPIb axis.
    Azzam K; Cissé-Thiam M; Drouet L
    Thromb Haemost; 1996 Jan; 75(1):203-10. PubMed ID: 8713802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinolytic and antiplatelet aggregation properties of a recombinant Cheonggukjang kinase.
    Radnaabazar C; Park CM; Kim JH; Cha J; Song YS
    J Med Food; 2011 Jun; 14(6):625-9. PubMed ID: 21554139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary.
    Linnemann B; Schwonberg J; Mani H; Prochnow S; Lindhoff-Last E
    J Thromb Haemost; 2008 Apr; 6(4):677-83. PubMed ID: 18182038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.
    Hosokawa K; Ohnishi T; Miura N; Sameshima H; Koide T; Tanaka KA; Maruyama I
    Thromb Res; 2014 Jan; 133(1):66-72. PubMed ID: 24268424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, antiplatelet and vasorelaxing activities of xanthone derivatives.
    Lin KW; Fang SC; Hung CF; Shieh BJ; Yang SC; Teng CM; Lin CN
    Arch Pharm (Weinheim); 2009 Jan; 342(1):19-26. PubMed ID: 19035386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin.
    Mehta AY; Mohammed BM; Martin EJ; Brophy DF; Gailani D; Desai UR
    J Thromb Haemost; 2016 Apr; 14(4):828-38. PubMed ID: 26748875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The promises of new antithrombotic agents].
    Camez A; Levy D
    Rev Prat; 1992 Nov; 42(17):2151-5. PubMed ID: 1290037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New antithrombotics in the prevention of venous thromboembolia and new anti-platelet drugs].
    Malý J; Pecka M; Malý R
    Vnitr Lek; 2011 Sep; 57(9):733-9. PubMed ID: 21957766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel perspectives for structuring synthetic inhibitors of human blood platelet aggregation and potential antithrombotic agents.
    Lasslo A
    Res Commun Chem Pathol Pharmacol; 1990 Aug; 69(2):133-62. PubMed ID: 2204096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of vintoperol on platelet aggregation and experimental thrombosis.
    Csomor K; Kárpáti E
    Arzneimittelforschung; 1994 Jan; 44(1):36-40. PubMed ID: 8135876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualized antithrombotic therapy.
    Lüscher TF; Steffel J
    Hamostaseologie; 2016; 36(1):26-32. PubMed ID: 25597592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships for selected sulfur-rich antithrombotic compounds.
    MacDonald JA; Langler RF
    Biochem Biophys Res Commun; 2000 Jul; 273(2):421-4. PubMed ID: 10873621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic activity of Z4A5, a new platelet glycoprotein IIb/IIIa receptor antagonist evaluated in a rabbit arteriovenous shunt thrombosis model.
    Jing BB; Li YX; Zhang H; Ren ST; Wang M; Li YP; Zang WJ; Wang B
    Thromb Res; 2011 Nov; 128(5):463-9. PubMed ID: 21924458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antithrombotic therapy in the elderly - are there differences?].
    Şahin M
    Turk Kardiyol Dern Ars; 2017 Sep; 45(Suppl 5):89-92. PubMed ID: 28976391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CLINICAL AND PHARMACEUTICAL ASPECTS OF THE USE OF ANTITHROMBOTIC DRUGS IN PATIENTS SUFFERING FROM ISCHEMIC HEART DISEASE (REVIEW).
    Zhunussov Y
    Georgian Med News; 2016 Feb; (251):32-9. PubMed ID: 27001783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.